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Core and associated symptoms within the
diagnosis of major depressive disorder
he current polythetic approach to diagnostic clas-
sification of “Major Depressive Disorder (MDD)”in the
Diagnostic and Statistical Manual of Mental Disorders.4th
ed. (DSM-IV)
1 or “Recurrent Depressive Episodes” in
The ICD-10 Classification of Mental and Behavioral
Disorders:Clinical descriptions and diagnostic guidelines.
(ICD-10)
2 is devoid of implications about etiopathology
or treatment response.Only “depressed mood”(mood)
or “loss of interest or pleasure in nearly all activities”
(anhedonia) are considered to be essential requirements
for the diagnosis of a Major Depressive Episode (MDE)
in DSM-IV.When these two “core symptoms”were used
to screen for MDD using a 2-item version of the Patient
Health Questionnaire (PHQ-2),they displayed a sensi-
tivity of 83% and a specificity of 92% for “caseness”
based on a Structured Clinical Interview for DSM-IV
(SCID)
3 and comparable results were obtained in a sub-
sequent European replication.
4
Confirmatory diagnosis of an MDE,according to DSM-
IV, requires a minimum of five symptoms (at least one
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The construct of major depressive disorder makes no eti-
ological assumptions about populations with diverse
symptom clusters. “Depressed mood” and “loss of inter-
est or pleasure in nearly all activities” are core features of
a major depressive episode, though a strong case can be
made to pay increasing attention to symptoms of fatigue,
sleep disturbance, anxiety, and neurocognitive and sexual
dysfunction in the diagnosis and evaluation of treatment
outcome. Mood, guilt, work, and interest, as well as psy-
chic anxiety, are consistently identified across validated
subscales of the Hamilton Depression Rating Scale as
prevalent and sensitive to change with existing treat-
ments. A major limitation of these antidepressant thera-
pies is their narrow spectrum of action. While the core
“mood and interest” symptoms have been the main focus
of attention, the associated symptoms listed above are
often unaffected or exacerbated by current treatments.
Careful clinical evaluation should address all of these
dimensions, recognizing that improvement may occur
sooner in some symptoms (eg, mood) compared with oth-
ers (eg, sleep disturbance).     
© 2008, LLS SAS Dialogues Clin Neurosci. 2008;10:271-277.being mood or anhedonia) for a minimum of 2 weeks (see
Table I for DSM-IV). It is easy to see how the multiple
permutations and combinations of these symptoms con-
tribute to substantial intraclass heterogeneity.
Major depressive episode subtypes
Specifiers may be added to imply greater homogeneity
within a subpopulation.For example,“with melancholic
features”requires at least three of the following symp-
toms: complete loss of pleasure, lack of reactivity, psy-
chomotor retardation,significant weight loss,excessive
guilt,or distinct quality of depressed mood.Some authors
have emphasized the presence of psychomotor retarda-
tion as a core feature of melancholic depression.
5 The
presence of “atypical features”requires two or more of
the following symptoms:overeating/weight gain,hyper-
somnia,leaden paralysis,preservation of mood reactivity,
or interpersonal rejection sensitivity. These latter two
symptoms (preservation of mood reactivity and interper-
sonal rejection sensitivity) have been criticized on the
basis of poor reliability,and some authors have recom-
mended that only the reverse vegetative symptoms,
hypersomnia,and overeating as well as leaden paralysis
form the core of atypical depression.
6
There have been attempts to dichotomize these two
depression subtypes on both treatment responsiveness
and psychobiology.Historically,tricyclic antidepressants
and electroconvulsive therapy were recommended for the
melancholic patient,
7 while patients with atypical features
appeared to respond better to classical monoamine oxi-
dase inhibitors
8,9 than to tricyclic antidepressants.These
distinctions have been less apparent with the current gen-
eration of selective serotonin reuptake inhibitor (SSRI)
and serotonin-norepinephrine reuptake inhibitors (SNRI)
antidepressants,and no currently available antidepressant
carries a specific indication for either melancholic or atyp-
ical symptoms.In fact,Parker’s group recently acknowl-
edged that symptom profiles within the “melancholia”
population may vary with age.Hypersomnia was noted to
be more common in the younger age group, while late
insomnia became the dominant sleep disturbance of older
patients.
10
Evidence of core symptoms from rating scales
It is common to evaluate the severity of a depressive
episode using classic rating scales, particularly the
Hamilton Rating Scale for Depression (HAMD-17)
11 or
the Montgomery Asberg Depression Rating Scale
(MADRS).
12 Differences in medication type and in the
symptom profiles of the population being evaluated may
influence outcomes on a rating scale.Among individual
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Five (or more) of the following symptoms have been present 
during the same 2-week period and represent a change from 
previous functioning; at least one of the symptoms is either: 
(1) Depressed mood or
(2) Loss of interest or pleasure 
Note: Do not include symptoms that are clearly due to a general 
medical condition, or mood-incongruent delusions or 
hallucinations. 
(1) Depressed mood most of the day, nearly every day, as indicated 
by either subjective report (eg, feels sad or empty) or observation 
made by others (eg, appears tearful). Note: In children and 
adolescents, can be irritable mood 
(2) Markedly diminished interest or pleasure in all, or almost all, 
activities most of the day, nearly every day (as indicated by either 
subjective account or observation made by others) 
(3) Significant weight loss when not dieting or weight gain (eg, 
a change of more than 5% of body weight in a month), or 
decrease or increase in appetite nearly every day. 
Note: In children, consider failure to make expected weight gains
(4) Insomnia or hypersomnia nearly every day 
(5) Psychomotor agitation or retardation nearly every day 
(observable by others, not merely subjective feelings of restlessness 
or being slowed down) 
(6) Fatigue or loss of energy nearly every day 
(7) Feelings of worthlessness or excessive or inappropriate guilt 
(which may be delusional) nearly every day (not merely s
elf-reproach or guilt about being sick) 
(8) Diminished ability to think or concentrate, or indecisiveness, 
nearly every day (either by subjective account or as observed by 
others) 
(9) Recurrent thoughts of death (not just fear of dying), recurrent 
suicidal ideation without a specific plan, or a suicide attempt or 
a specific plan for committing suicide 
Table I. DSM-IV criteria for Major Depressive Episode.
Selected abbreviations and acronyms
MDD Major Depressive Disorder
HAM-D Hamilton Rating Scale for Depression
MDE Major Depressive Episode
DSM Diagnostic and Statistical Manual of Mental
Disorders
ICD International Classification of Diseasesitems, the core “depressed mood” item on either the
HAMD-17 or the MADRS was more sensitive to drug-
placebo separation and to establishing optimal dosing,
compared with the full scales in several controlled tri-
als.
13,14
The sensitivity of some items to differentiate between
active drug and placebo can be compromised when a drug
has an unfavorable effect on certain items.For example,
increased anxiety may occur during the early weeks of
SSRI therapy,and activating antidepressants may disrupt
some aspects of sleep.
15 The net result is that prevalent
items may not emerge on rating scales that are designed
to detect improvements during antidepressant therapy.
When symptom prevalence and sensitivity to change have
been evaluated in large data sets using item analysis or
factor analysis, several core symptoms emerge with
greater sensitivity to change and less distortion by treat-
ment emergent side effects than with the full versions of
the scale.
Three such scales derived from the HAMD-17 are the
“Bech 6,”
16“Maier subscale,”
17 and “HAMD-7”
18 (Table
II).Four items are common to each of these scales:mood,
guilt, anhedonia, and psychic anxiety. In HAMD-7 and
Bech 6,loss of energy (fatigue) was also present,as was
psychomotor retardation in Bech 6 and Maier 6,while the
HAMD-7 included somatic anxiety and suicidal ideation.
All three scales include anxiety symptoms,in contrast to
current diagnostic systems.
The prominence of anxiety symptoms 
and syndromes
Surprisingly,anxiety is not considered as a core or associ-
ated symptom of depression according to either DSM-IV
or ICD-10 criteria.Neither is “with anxious features”a
specifier within DSM-IV,yet up to 90% of patients have
co-occurring anxiety symptoms,and approximately 50%
of depressed patients meet criteria for a comorbid anxi-
ety disorder.
19,20This lack of syndrome independence on
Axis I is a major limitation to the current concept of
comorbidity.Comorbid disorders should only exist at a
level expected by chance,yet in the case of MDD,comor-
bidity is the rule and not the exception.
21
A recent proposal for mood and anxiety spectrum disor-
ders,to be considered in DSM-V,has been advanced by
Watson
22 who proposes three subclasses of emotional dis-
orders:“bipolar disorders,”“distress disorders,”(MDD,
dysthymic disorder, generalized anxiety disorder, and
post-traumatic stress disorder) and “fear disorders”(panic
disorder,agoraphobia,social phobia and specific phobia).
This reflects a pendulum swing to the unitary position of
Mapother
23 and Lewis
24 who viewed states of anxiety
along a continuum with depressive disorders,in contrast
to the progressive separation of mood and anxiety disor-
ders initiated more than three decades ago.
25,26 It is likely
that the inconsistent impact of some antidepressants on
anxiety has distorted measurement of anxiety symptoms
during treatment.
What is less in dispute is the impact of anxiety comorbid-
ity on response to the treatment of depression.Patients
without anxiety symptoms at the time of remission are sig-
nificantly more likely to remain well than those patients
with residual anxiety.
27There is also consistent evidence of
lower response rates and higher relapse in comorbidly
anxious depressed patients.Although there is a strong jus-
tification to consider “anxious depression”as a depressive
subtype,
28 a case can be made to maintain the separation
of Generalized Anxiety Disorder (GAD) from MDD.
29
Sleep disturbance, apathy, and fatigue
Sleep disturbance 
The relationship between sleep and depression is com-
plex.Insomnia is a frequent symptom of depression,and
there is evidence to suggest that sleep disturbances are
often a prodrome to a MDE.
30 Paradoxically,sleep depri-
vation has been advocated as an antidepressant therapy
31
while several antidepressant agents actually worsen
sleep.
15 Sleep disturbance also lends itself to objective
evaluation through polysomnography.Disturbances in the
ratio of rapid eye movement (REM) sleep to non-REM
sleep,decreased slow-wave sleep,and impaired sleep con-
tinuity are among the most robust markers for MDD.
Whether reductions in slow-wave sleep and REM latency
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MAIER-6 HAMD-7 BECH-6
Mood Mood Mood
Guilt Guilt Guilt
Work and interest Work and interest Work and interest
Psychic anxiety Psychic anxiety Psychic anxiety
Agitation Energy Energy
Retardation Somatic anxiety Retardation
Suicide
Table II. Core symptoms from three scales derived from the Hamilton
Depression Rating Scale.are trait or state abnormalities is a controversial issue,
32
and attempts to establish robust diagnostic electroen-
cephalographic markers for MDD have been confounded
by the effects of age and gender.
33
Among the symptoms of depression,sleep disturbance is
a prominent symptom that is frequently unresponsive to
current antidepressants,or is overtreated with consequent
daytime somnolence.In a family practice evaluation of
physician diagnosis and patient self-report of depressive
symptoms, “insomnia or hypersomnia” along with
“depressed mood”were the symptoms most frequently
elicited by physicians,although only “suicidal ideation”
and “insomnia or hypersomnia”were associated with a
statistically significant likelihood of depression diagno-
sis.
34 Middle (71%),early (62%),and late (55%) insom-
nia were frequently reported items from the HAMD-17
in a sample of almost 300 depressed clinic patients.
18
However,underscoring the limited effectiveness of cur-
rent antidepressants to improve sleep,none of these three
sleep items were among the seven with greatest sensitiv-
ity to change during treatment (Table III).In fact,middle
insomnia emerged as the eighth most sensitive item to
reflect antidepressant change.
18
The importance of sleep disturbance as a residual symp-
tom in MDD has also been highlighted by Nierenberg
and colleagues,
35 who examined threshold and subthresh-
old symptoms among patients who achieved remission
(HAMD-17″ 7) after 8 weeks of antidepressant treatment
with fluoxetine.The three most prevalent residual symp-
toms were disturbances in sleep (44%), fatigue (38%),
and anhedonia (27%).Since the majority of these patients
reported sleep disturbance prior to treatment with fluox-
etine it is less likely to have been a treatment-emergent
adverse event.The persistence of insomnia is a particular
concern, given the propensity for residual sleep distur-
bance to predict relapse.
36
Persistent sleep disturbances in SSRI “responders”
include prolonged sleep latency (beyond 1 hour),reduced
total sleep time, and multiple awakenings. Although
coprescription of a hypnotic may have a beneficial effect,
37
concerns about long-term hypnotic use limit this recom-
mendation.Elsewhere,advantages beyond sleep restora-
tion were demonstrated when eszopiclone and fluoxetine
were combined in the acute treatment of MDD.
38 Given
the role of sleep disruption in predicting relapse,there is
a strong argument to consider sleep disturbance as a core
symptom in depression,and to emphasize the importance
of sleep restoration early in the treatment of an MDE.
The daytime effects of persistent sleep disruption should
not be underestimated in depressed patients.
Fatigue and apathy
Particularly in primary care settings,depressed patients
are likely to present with complaints of exhaustion or
inability to carry out physical or mental work. In fact,
fatigue was the commonest depressive symptom in a sur-
vey of family practice settings.
39 In the large European col-
laborative study of almost 2000 depressed patients across
6 countries (DEPRES II), 73% of patients “felt tired”;
this symptom was associated with severity of the episode
and was more prevalent in women.
40Although “fatigue or
loss of energy nearly every day” is not considered an
essential depressive symptom according to DSM-IV,it is
emphasized within the atypical symptom cluster, with
“leaden paralysis” as the extreme variant. However,
reduced energy is considered a “core feature”in the def-
inition of depressive episode according to ICD-10,
emphasizing that marked tiredness may occur after only
slight effort.
41 It is a reasonable assumption that sleep dis-
turbance and daytime fatigue are related (as previously
reviewed—over 40% of remitters to fluoxetine had sleep
disturbance and just under 40% had fatigue),although
there are no data to confirm this relationship.
Similarly,apathy may overlap with diminished interest,
loss of energy,and even indecisiveness,but this construct
is too nonspecific to be considered a core symptom. In
fact,apathy has been reported more frequently as a side
effect in up to 20% of patients who receive SSRI antide-
pressants.
42
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Symptom from Percent endorsement Change score 
HAMD-17 Cohen’s d
M F All
Work & interest 99 98 99 1.84
Depressed mood 98 98 98 1.81
Anxiety-somatic 86 92 90 1.03
Suicide 77 72 73 0.88
Energy 98 94 95 0.88
Guilt 86 85 85 0.86
Anxiety-psychaitric 59 90 79 0.83
Table III. HAMD-7: A brief measure of remission. HAMD, Hamilton
Rating Scale for Depression 
Adapted from ref 20: McIntyre R, Kennedy S, Bagby RM, et al. Assessing
full remission. J Psychiatry Neurosci. 2002;27:235-239. Copyright ©
Canadian Medical Association 2002Cognitive dysfunction
Subjective neurocognitive disturbance in depression is
represented by “diminished ability to think or concen-
trate”in DSM-IV,although broader neurocognitive dis-
turbances can be measured using standardized neu-
ropsychological test batteries.Neuropsychological deficits
have most often been detected in older individuals and
include disturbances in psychomotor speed,
43 memory,
44
verbal fluency,
45 attention,
45 executive function,
45 and pro-
cessing speed.
48Whether restoration of cognitive function
occurs with symptom remission in MDD has been a topic
of considerable interest in recent years.Mostly in elderly
patients,the data suggest enduring deficits in both mem-
ory and executive function.
49 Links between recurrent
depressive episodes,reduced hippocampal volume and
memory deficits have also been reported.
50Although it is
premature to endorse any specific neurocognitive deficit
as a core symptom of depression,residual memory dis-
turbance has major implications for functional recovery
and deserves ongoing attention in clinical management.
Sexual dysfunction
Sexual dysfunction is also a complex issue among patients
with depression.Common complaints include reduction in
desire or libido, diminished arousal, a decline in the fre-
quency of intercourse,or an undesirable delay in achieving
orgasm.The prevalence of sexual dysfunction in the com-
munity is high;
51 it is even higher in untreated depressed
patients
52 and may be further exacerbated by antidepres-
sants.
53 In a large European study designed to evaluate sex-
ual function in both treated and untreated depressed
patients,more than two thirds of men and women reported
decreased libido and the prevalence increased with sever-
ity and duration of the depressive episode.
54
The reluctance among many patients to spontaneously
report sexual dysfunction as a disturbing symptom of
depression has resulted in a relatively low and misleading
prevalence rate.The true importance of sexual dysfunc-
tion as a depressive symptom has not been recognized
either in diagnosis or during antidepressant therapy.
Nevertheless,low libido may contribute to deteriorating
interpersonal/marital relations and further exacerbate
depression. In the case of SSRI antidepressants, up to
60% of patients report treatment-emergent sexual func-
tion.
55,56Antidepressants that do not stimulate serotonin
release are less likely to induce or exacerbate sexual dys-
function.
53,57,58This has implications for treatment adher-
ence,as sexual dysfunction remains one of the common-
est reasons for treatment discontinuation.
53
Future directions
Both DSM-IV and ICD-10 represent descriptive systems
of classification.With DSM-V in mind, several authors
have advocated a role for phenotypic characteristics,
genetic data,as well as cognitive or other biological mark-
ers.
59,60 Endophenotypes reflect the gap between the gene
and the expression of the disease process.In depression,
putative biological candidates include disruptions in cir-
cadian rhythm,immune function,neurotransmitter-recep-
tor signaling pathways,and neuroendocrine axes,as well
as brain structure and function. Studies exploring the
influence of gene-environment interactions (involving
polymorphisms of the serotonin transporter) on symptom
presentation and treatment response in depression have
attracted considerable attention.
59,60 Reduction in hip-
pocampal volume has been consistently reported in
MDD
63 and linked to duration of untreated depression,
64
as well as deficits in neurocognition.
50There are also pre-
liminary reports on potential markers for treatment resis-
tance.Lower serotonin transporter binding in the mid-
brain, medulla, and anterior cingulate cortex was
associated with nonremission,
65 while hypermetabolism in
the ventral anterior cingulate area brain region was a pre-
dictor of nonresponse to both cognitive therapy and ven-
lafaxine.
66Though provocative,these interesting findings
are unlikely to influence diagnostic or treatment selection
practices in the near future.In the meantime,a re-exam-
ination of core symptoms in depressed patients and care-
ful clinical attention to their response to disparate anti-
depressant strategies will remain the cornerstone of good
clinical practice. ❏
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Síntomas centrales del trastorno depresivo
mayor: relevancia para el diagnóstico y el
tratamiento
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Symptômes essentiels des troubles 
dépressifs majeurs : importance pour le 
diagnostic et le traitement
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sive » et « la perte d’intérêt ou de plaisir dans
presque toutes les activités » sont des critères essen-
tiels d’un épisode dépressif majeur, bien qu’il y ait
beaucoup à dire sur l’intérêt croissant que suscitent
les symptômes de fatigue, les perturbations du som-
meil, l’anxiété et les dysfonctions sexuelles et cogni-
tives dans le diagnostic et l’évaluation du traite-
ment. Des sous-échelles validées de l’HAMD
(Hamilton Depression Rating Scale) montrent régu-
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